Le Lézard
Classified in: Health, Business
Subjects: SLS, MRR

Sunrise Group among the world's top ten chemical distributors


NEW YORK, May 22, 2023 /PRNewswire/ -- LEADING Chinese chemical distribution company Sunrise Group has secured a global ranking of tenth place and third place in the Asia-Pacific region on the latest ICIS Top 100 Chemical Companies list. According to its latest financial report, Ningbo-based Sunrise Group generated US$ 3.6 billion in sales.

In 2022, the company expanded into the pharmaceutical sector, acquiring Taizhou Dachen Pharmaceutical, a firm specializing in R&D and manufacturing of pharmaceutical raw materials and intermediates such as pyrazole and sitagliptin side chain. Taizhou Dachen Pharmaceutical generates an annual output of US$ 58 million. The deal has strengthened Sunrise Group's competitive advantage within the API and intermediate market. It has also paved the way for entry into the higher-end pharmaceutical preparation market.

Sunrise Group attributes its growth in sales to its ability to adapt to market changes quickly and optimize its product quality, service level, and supply chain management. This ability has enabled the company to increase its sales performance by 41% year-on-year in 2022, with a growth rate of 14% for customers and 10% on products.

The company has also modernized its warehouse and logistics center and launched a new brand image to reflect its growth within a changing market. Sunrise Group is committed to strengthening collaboration with its valued suppliers and customers worldwide and ensuring a unique contribution to the chemical distribution industry.

The company anticipates challenges in the export of China's chemical products in 2023 due to unfavorable geopolitical tensions, rising interest rates, and high inflation. However, Sunrise Group remains optimistic about the future market potential stimulated by the RCEP and economic growth in ASEAN and other regions. The company intends to leverage its expertise in chemical distribution and collaborate with its partners to advance technological innovation and market expansion in these fields. Despite the challenges of a highly competitive and dynamic industry, Sunrise Group has maintained its strength and continues to position itself at the forefront of industry innovation.

It looks forward to sustainable human health development. To learn more about Sunrise Group's services, interested parties can contact Sunrise Group to learn more about its services or email [email protected], or visit its website at www.sunrisechemical.com.

SOURCE Sunrise Group


These press releases may also interest you

at 18:42
George Weston Limited Announces Election of Directors
George Weston Limited ("Weston" or the "Company") today announced that all of the nominee directors listed in its management proxy circular dated March 19, 2024, were elected as directors of the Company. The vote was conducted at the Company's...

at 18:41
Family Source Consultants' New Modern Client-Focused Office for Surrogacy Agency Set to Revolutionize Family-Building Services
Family Source Consultants, LLC, a leading provider of surrogacy, egg donation, and all third-party reproduction services, is excited to announce the grand opening of its new state-of-the-art office dedicated to enhancing the journeys of intended...

at 18:15
Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024
Fennec Pharmaceuticals Inc. , a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2024 financial results before the opening of the U.S. financial markets on Tuesday, May 14, 2024....

at 18:00
Denny's Canada invites guests to enjoy a sweet treat in support of women's health
In recognition of Mother's Day on May 12th, Denny's Canada is delighted to announce that they have partnered with Women's Health Collective Canada (WHCC) to host a special fundraiser. From May 7th to 12th, in participating stores across Canada, $2...

at 17:41
Newly Published Data in JAMA Cardiology Demonstrates Favorable Long-term Effects of the Corvia Atrial Shunt in Heart Failure Patients
Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today announced the publication in JAMA Cardiology of two-year echocardiographic data from its REDUCE LAP-HF II randomized clinical trial of the Corvia® Atrial...

at 17:09
FDA Roundup: May 7, 2024
Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a meeting of the Psychopharmacologic Drugs Advisory Committee on June 4 to discuss a new drug application for...

More news about Health...


News published on and distributed by: